European Management Platform for Childhood Interstitial Lung Diseases

Publication Guidelines

All planned publications which rely on work done with data or biomaterials of the chILD-EU **register** should be submitted to the management committee of the chILD-EU **register** for coordination.

In the publications the support of the chILD-EU **register** must be acknowledged: "This work was supported by the European Register and Biobank on Childhood Interstitial Lung Diseases (chILD-EU **register**) funded by the European Commission under FP7-HEALTH-2012-INNOVATION-1, HEALTH.2012.2.4.4-2: Observational trials in rare diseases".

Authors and Contributors will disclose to readers of the contributions made to the research and to the manuscript, so that they can accept both credit and responsibility.
Authors must have satisfied all three conditions:
1. Contributed substantially to the conception and design of the study, the acquisition of data, or the analysis and interpretation.
2. Drafting or providing critical revision of the article.
3. Provided final approval of the version to be published.

All Contributors to a project must be named in a "study group" which will also be listed among the authors, in order to enhance the integrity of publication. It will contain the names of the responsible persons (physicians, study coordinators, scientists) and the respective institution. If applicable the number of completely documented subjects, and other relevant details to the project and to describe the contribution, must be indicated.

Description of individual cases, collection of similar cases, description of their data and analysis of biomaterials. Legal permission and ethical approval for these projects is covered by the patient's informed consent and participation in the project. All Participants who contributed subjects to the chILD-EU **register** will be named in a publication in alphabetical order excluding first and last authorship, which are primarily determined by the degree of contribution to the project. If the limiting number of authors on a publication is not reached, the contributing Participants will be named as co-authors. If the limiting number of authors on a publication is reached, those who contributed more than 20% of the cases will be named as co-authors, the others will be named as members of the study group. Care is taken to make the members of the study group searchable in Pubmed.

Prospective observations and clinical trials. For these projects, selected by the responsible board of the chILD-EU**,** comprehensive clinical study protocols, all relevant and necessary legal and administrative procedures, the ethical applications and informed consent forms must be obtained before patients can be approved for the actual participation. This must be organized by the sponsor and principal investigator of the project. These projects are led by Sub-Study trial panels, consisting of a principal investigator, the national trial coordinator, the trial manager and the trial statistician. Authorship is recommended to be clarified before start of the study and may be organized similar as for the above indicated projects.

Independently of the performance of his own project, each Participant shall also contribute to the success of the chILD-EU **register**. Every new study will be announced on the website of the chILD-EU including title, aim, methods, and the study coordinator, as well as under clinicaltrials.gov (www.clinicaltrials.gov) and will be advertised for directly to all members of the chILD-EU.

Version 1.0 (2014-04-03)